

EUROPEAN CURRICULUM VITAE**PERSONAL INFORMATION**

Name	BURGIO SALVATORE LUCA
Address	
Telephone	
Fax	
E-mail	salvatorelucaburgio@gmail.com
Nationality	ITALIAN
Date of birth	13/AUG/1982
Medical license/Reg. no.	Albo Provinciale dei Medici Chirurghi di FORLÌ-CESENA (Ordine della Provincia di FORLÌ-CESENA) n. 4735

EDUCATION AND TRAINING-WORK EXPERIENCE/ ISTRUZIONE E FORMAZIONE-ESPERIENZE LAVORATIVE

Dates (from to)	<i>October 2001-October 2007</i> Degree in General Medicine and Surgery at the University of Palermo (classe 46/S), 110/110 cum laude. Thesis: “Hormone refractory prostate cancer in advanced disease: potential response factors (CgA e VEGF) in combination treatment Docetaxel plus Somatostatin analogue.” <i>September 2003-July 2006</i> Clinical activities at the Emergency Room unit of St. Elia Hospice in Caltanissetta (CL). <i>January 2006- September 2007</i> Clinical activities at the Department of Internal Medicine of St. Elia Hospice in Caltanissetta (CL). <i>January 2008- March 2008</i> Licence to exercise the Medical profession (University of Palermo). <i>March 2008 –March 2012</i> Specialization in Medical Oncology (maximum marks) , University of Ferrara affiliated with the Department of Oncology at IRCCS-IRST Istituto Tumori della Romagna. During specialization member of the “Home Care Service” of Forlimpopoli Hospice and Dovadola Hospice (palliative and analgesic therapies). From April 2012 specialist in oncology at IRCCS-IRST Istituto Tumori Romagna, Meldola (FC) Tutor on cancer prevention for the following associations: IOR (Istituto Oncologico Romagnolo) LOTO (gynecological tumors) LILT (Lega Italiana per la Lotta contro i Tumori) MOVEMBER (prostate cancer and testicular cancer).
Name and address of the company	IRCCS-IRST ISTITUTO TUMORI DELLA ROMAGNA, Via Piero Maroncelli

Type and field of activity	40, 47014 Meldola
Principal subjects-occupational skills covered	Since April 2012 oncologist engaged in day service activities, hospitalization, outpatient activities, palliative and analgesic therapies, research activities, and active participation in multidisciplinary groups of urological oncology and gynecological oncology.
Title of qualification awarded	Principal investigator and co-investigator of several scientific protocols of urological oncology and gynecological oncology. Oncologist

Main subjects and professional skills related to the education awarded	1. Management and treatment of urological and gynecological tumors; 2. Palliative and analgesic therapies 3. Oral chemotherapies and innovative cancer therapies
---	--

PERSONAL SKILLS AND EXPERTISE (Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas).

Ability to work in stressful situations, especially related to the relationship with the public and to deadlines for work activities

Ability to adapt to different working contexts, acquired during my experiences professionals in different departments

Participation and passing of the Course for Performer of BLSD - Basic Life Support - Defibrillation (Basic Cardiopulmonary Resuscitation with use of Semi-automatic Defibrillators DAE), held at the Morgagni-Pierantoni Hospital in Forlì (2022)

Qualification and passing of the course "high risk fire emergency teams" (2020)

Since 2010 member of the urological multidisciplinary team at IRCCS-IRST Istituto Tumori della Romagna, Meldola (FC), with clinical experience in the diagnosis, management and treatment of all urological tumors

Since 2010 member of the gynecological multidisciplinary team at IRCCS-IRST Istituto Tumori della Romagna, Meldola (FC), with clinical experience in the diagnosis, management and treatment of all gynecological tumors.

Since September 2018 active participation in multidisciplinary meetings on gynecological tumors "AREA VASTA ROMAGNA"

Since September 2018 active participation in multidisciplinary meetings on urological tumors "AREA VASTA ROMAGNA"

Active participation in the drafting of the regional PDTA on the diagnosis and treatment of endometrial cancer.

Since 2022 consultant activity abroad (Republic of San Marino) for the management and treatment of complex cases of gynecological and urological tumors, actively participating in the related multidisciplinary activities.

Principal investigator and co-investigator in several national and international clinical trials (urological and gynecological tumors).

PROFESSIONAL MEMBERSHIP: AIOM (Italian Society for Medical Oncology)

Up to date with ECM credits (field training)

Mother tongue <i>Madrelingua</i>	[Specify mother tongue] Italian
--	------------------------------------

Other languages <i>Altre lingue</i>	English
Reading skills <i>Capacità di lettura</i>	Good
Writing skills <i>Capacità di scrittura</i>	Good
Verbal skills <i>Capacità di espressione orale</i>	Good

Organisational skills and expertise Coordination and management of Human Resources, projects and budgets; at work, in voluntary work (ig. culture and sports) and at home, etc.	Good attitude to the management of projects and groups, good sense of organization. Great team spirit, ability to adapt to multicultural environments, good communication skills. Singer in choir at church and in Department Of Pediatrics at St. Elia Hospital in Caltanissetta (CL) during secondary school and University.
Technical skills and expertise – <i>Computer, special machineries and devices</i>	Good knowledge of the Office package (Word, Power Point, Excel) and the Internet Good knowledge of the procedures relating to the compilation of medical records in electronic format Good knowledge of the procedures relating to the use of the AIFA platform
Artistic abilities Music, writing, design, etc.	Singing, photograph, poetry, botany, zoology, painting
Driving licence and other authorizations	Driving license for car and motorcycle (A+B)
ANNEXES	Publication list: Original articles: 1. Perspectives on mTOR inhibitors for castration-refractory prostate cancer. S.L. Burgio, F.Fabbri, I.J. Seymour, W. Zoli, D. Amadori, U. De Giorgi 2. Alpha-Fetoprotein Surge Following High-Dose Chemotherapy in Germ Cell Tumors. S. L. Burgio - C. Menna - G. Papiani - A. C. Gardini - N. De Luigi¹ - R. Corsi - G. Rosti. Journal of Chemotherapy 3. Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): an observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone). Genestreti G, Ampollini L, Burgio MA, Rolli L, Sanna S, Scarpi E, Monti M, Burgio SL, Giannone L, Santo A, Mezzetti M, Casanova C, Buosi R, Rusca M, Amadori D, Gavelli G. 4. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma M Santoni, U De Giorgi, R Iacovelli, A Conti, L Burattini, L Rossi, S Luca Burgio, R Berardi, G Muzzonigro, E Cortesi, D Amadori, and S Cascinu 5. The emerging role of anti-angiogenic therapy in ovarian cancer (review). Conteduca V, Kopf B, Burgio SL, Bianchi E, Amadori D, De Giorgi U. 6. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Burgio SL, Conteduca V, Menna C, Carretta E, Rossi L, Bianchi E, Kopf B, Fabbri F, Amadori D, De Giorgi U. 7. PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer. Burgio SL, Conteduca V, Rudnas B, Carrozza F, Campadelli E, Bianchi E, Fabbri P, Montanari M, Carretta E, Menna C, De Giorgi U. 8. High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer. Rossi L, Santoni M, Crabb SJ, Scarpi E, Burattini L, Chau C, Bianchi E, Savini A, Burgio SL, Conti A, Conteduca V, Cascinu S, De Giorgi U. 9. Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Conteduca V, Burgio SL, Menna C, Carretta E, Rossi L, Bianchi E, Masini C, Amadori D, De Giorgi U.

10. ¹¹¹In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance. Genestreti G, Bongiovanni A, Burgio MA, **Burgio SL**, Musto A, Rossi A, Monti M, Scarpi E, Ulivi P, Bravaccini S, Dubini A, Matteucci F, Gavelli G.
11. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Veccia A, Conteduca V, Maines F, Galligioni E.
12. Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer. Santoni M, Crabb SJ, Conti A, Rossi L, Burattini L, Conteduca V, Chau C, Burgio SL, Muzzonigro G, Cascinu S, De Giorgi U
13. Early outcome prediction on ¹⁸F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E, Fabbri F, Carretta E, Amadori D, Paganelli G, Matteucci F.
14. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C, Moretti A, Galassi R, Rossi L, Amadori D, Paganelli G, Matteucci F.
15. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Salvi S, Casadio V, Conteduca V, Burgio SL, Menna C, Bianchi E, Rossi L, Carretta E, Masini C, Amadori D, Calistri D, Attard G, De Giorgi U.
16. Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. Caffo O, Ortega C, Di Lorenzo G, Sava T, De Giorgi U, Cavaliere C, Macrini S, Spizzo G, Aieta M, Messina C, Tucci M, Lodde M, Mansueto G, Zucali PA, Alesini D, D'Angelo A, Massari F, Morelli F, Procopio G, Ratta R, Fratino L, Lo Re G, Pegoraro MC, Zustovich F, Vicario G, Ruatta F, Federico P, La Russa F, Burgio SL, Maines F, Veccia A, Galligioni E.
17. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer Antonello Veccia, Orazio Caffo, Ugo De Giorgi, Giuseppe Di Lorenzo, Cinzia Ortega, Florinda Scognamiglio, Michele Aieta, Gaetano Facchini, Giovanni Mansueto, Rodolfo Mattioli, Giuseppe Procopio, Vittorina Zagonel, Alessandro D'Angelo, Gilbert Spizzo, Roberto Bortolus, Maddalena Donini, Giovanni Lo Re, Francesco Massari, Giovanni Vicario, Paolo A Zucali, Daniele Alesini, Andrea Bonetti, Claudia Mucciarini, Maurizio Nicodemo, Alfredo Berruti, Lucia Fratino, Michele Lodde, Caterina Messina, Alessandra Perin, Daniele Santini, Teodoro Sava, Marcello Tucci, Umberto Basso, Francesca Maines, Luca S Burgio, Enzo Galligioni.
18. CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone. Salvi S, Casadio V, Burgio SL, Conteduca V, Rossi L, Menna C, Carretta E, Costantini M, Zoli W, De Giorgi U.

19. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. Farolfi A, Schepisi G, Conteduca V, Burgio SL, Lolli C, De Giorgi U.
20. Vitamin D status among long-term survivors of testicular cancer. Schepisi G, De Padova S, Scarpi E, Lolli C, Gurioli G, Menna C, Burgio SL, Rossi L, Gallà V, Casadio V, Salvi S, Conteduca V, De Giorgi U.
21. A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer. Lolli C, Gallà V, Schepisi G, Barone D, Burgio SL, Maugeri A, Vertogen B, Amadori D, De Giorgi U.
22. Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer. Conteduca V, Scarpi E, Caroli P, Salvi S, Lolli C, Burgio SL, Menna C, Schepisi G, Testoni S, Gurioli G, Paganelli G, Casadio V, Matteucci F, De Giorgi U.
23. AR Copy Number and AR Signaling-directed Therapies in Castration-resistant Prostate Cancer. Salvi S, Conteduca V, Lolli C, Testoni S, Casadio V, Zaccheroni A, Rossi L, Burgio SL, Menna C, Schepisi G, De Giorgi U.
24. Association among metabolic syndrome, inflammation, and survival in prostate cancer. Conteduca V, Caffo O, Galli L, Maugeri A, Scarpi E, Maines F, Chiuri VE, Lolli C, Kinspergher S, Schepisi G, Santoni M, Santini D, Fratino L, Burgio SL, Salvi S, Menna C, De Giorgi U.
25. Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. Conteduca V, Scarpi E, Salvi S, Casadio V, Lolli C, Gurioli G, Schepisi G, Wetterskog D, Farolfi A, Menna C, De Lisi D, Burgio SL, Beltran H, Attard G, De Giorgi U.
26. Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. Conteduca V, Gurioli G, Rossi L, Scarpi E, Lolli C, Schepisi G, Farolfi A, De Lisi D, Gallà V, Burgio SL, Menna C, Amadori A, Losi L, Amadori D, Costi MP, De Giorgi U.
27. Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches. Farolfi A, Gurioli G, Fugazzola P, Burgio SL, Casanova C, Ravaglia G, Altavilla A, Costantini M, Amadori A, Framarini M, Ansaloni L, De Giorgi U.
28. Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver Support. De Padova S, Casadei C, Berardi A, Bertelli T, Filograna A, Cursano MC, Menna C, Burgio SL, Altavilla A, Schepisi G, Prati S, Montalti S, Chovanec M, Banna GL, Grassi L, Mego M, De Giorgi U.
29. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide. Lolli C, De Lisi D, Conteduca V, Gurioli G, Scarpi E, Schepisi G, Ravaglia G, Menna C, Farolfi A, Altavilla A, Burgio SL, Tonini G, Santini D, De Giorgi U.
30. Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. Schepisi G, Brighi N, Cursano MC, Gurioli G, Ravaglia G, Altavilla A, Burgio SL, Testoni S, Menna C, Farolfi A, Casadei C, Tonini G, Santini D, De Giorgi U.
31. Plasma Androgen Receptor in Prostate Cancer. Conteduca V, Gurioli G, Brighi N, Lolli C, Schepisi G, Casadei C, Burgio SL, Gargiulo S, Ravaglia G, Rossi L, Altavilla A, Farolfi A, Menna C, Colangione SP, Pulvirenti M,

	Romeo A, De Giorgi U. 32. Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. Conteduca V, Scarpi E, Matteucci F, Caroli P, Ravaglia G, Fantini L, Gurioli G, Schepisi G, Wetterskog D, Menna C, Burgio SL, Lolli C, Paganelli G, Attard G, De Giorgi U. 33. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. Altavilla A, Casadei C, Lolli C, Menna C, Ravaglia G, Gurioli G, Farolfi A, Brighi N, Conteduca V, Burgio SL, Schepisi G, Rossi L, Gargiulo S, Lisotti I, De Giorgi U. 34. Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors. Schepisi G, Conteduca V, Casadei C, Gurioli G, Rossi L, Gallà V, Cursano MC, Brighi N, Lolli C, Menna C, Farolfi A, Burgio SL, Altavilla A, Martinelli G, De Giorgi U. 35. Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma. Conteduca V, Scarpi E, Farolfi A, Brighi N, Rossi L, Gurioli G, Lolli C, Schepisi G, Bleve S, Gianni C, Virga A, Altavilla A, Burgio SL, Menna C, De Giorgi U.
--	---

I authorize the processing of personal data pursuant to the GDPR and Legislative Decree 30 June 2003, no. 196 "Code regarding the protection of personal data" for the purposes of search and selection of personnel and business contacts.

Date: _____

Signature: _____